Cardiovascular Disease Clinical Trial
Official title:
Comparisons of Postoperative BIS Profile and Extubation Time After Valvular Heart Surgery: Remifentanil-based Propofol-supplemented Versus Sevoflurane-sufentanil Balanced Anesthesia Regimen
Background: Although remifentanil based anesthesia has been preferred for fast-track cardiac
anesthesia, its recovery profile in cognitive function has not been investigated. Authors
determined postoperative Bispectral index (BIS) score as well as extubation time after
remifentanil-based propofol-supplemented anesthesia and compared them with those after
conventional balanced sevoflurane-sufentanil anesthesia.
Methods: Patients undergoing cardiac surgery using moderate hypothermic cardiopulmonary
bypass (CPB) will be randomly allocated to get remifentanil-based propofol-supplemented
(Group R) or conventional sevoflurane-sufentanil regimen (Group C) in the study period. For
anesthetic induction and maintenance, fixed target controlled infusion (TCI) of remifentanil
(plasma concentration 20 ng/ml) and TCI-propofol for maintaining BIS score 40-60 (effect
concentration 0.8-1.5 μg/ml) in Group R, and TCI-sufentanil (Cp 0.4- 0.8 ng/ml) and
sevoflurane inhalation for maintaining 80-120 % of baseline BP and BIS < 60 (< 1.5 MAC) in
Group C, respectively.
Authors will analyze postoperative recovery of cognitive function by using BIS after the use
of remifentanil-based propofol-supplemented anesthesia for cardiac surgery and to compare
them to those after the use of conventional balanced sevoflurane-sufentanil anesthesia.
Backgrounds Since opioid-based anesthesia does not produce dose-dependent myocardial
depression, it has been applied for patients undergoing cardiac surgery with myocardial
dysfunction.
However, prolonged use of conventional opioids in a large dosage delays patient's
postoperative recovery due to their longer half-life and accumulation of their metabolites.
Fast-track cardiac anesthesia which reducing the duration of postoperative mechanical
ventilation and length of stay (LOS) in the intensive care unit (ICU) is beneficial not only
in reducing ventilator-related complications and medical expense but in improving patient's
outcome.
For this purpose, in addition to supplementation of neuraxial blockade, use of short-acing
opioid, such as remifentanil, has been advocated for cardiac anesthesia. Remifentanil is an
ultra-short acting opioid and provides not only stable hemodynamics, as other opioid does,
and but fast recovery, even after prolonged use in a large dosage. In further, recent
investigations showed that remifentanil provides preconditioning effect in myocardial
ischemia injury during cardiac surgery, as like in the use of volatile anesthetics including
sevoflurane.
Remifentanil vs volatile anesthetics In spite of the importance of recovery of cognitive
function on whole postoperative clinical features, most investigations have evaluated only
the postoperative respiratory profile in determining the speed of postoperative recovery
specific to the choice of anesthesia regimen.
Bispectral index (BIS) monitoring has been used to monitor sedation depth, to avoid
introperative awareness and to adjust the dosage of intraoperative hypnotics. Several
investigations tried to find BIS's efficacy in managing sedation of critically ill patients.
In spite of some controversies, BIS monitoring seem to be beneficial: it does not require
additional stimuli to determine sedation level which is essential in other subjective
modalities, such as Ramsay score, and usually compromises the already instituted patient's
sedation level.
Authors will analyze postoperative recovery of cognitive function by using BIS as well as
respiratory profiles after the use of remifentanil-based propofol-supplemented anesthesia for
cardiac surgery and to compare them to those after the use of conventional balanced
sevoflurane-sufentanil anesthesia.
Methods Population and Study Protocol After obtaining Institutional Review Board approval and
informed consents from the patients, they are prospectively studied among patients undergoing
cardiac valve repair or replacement surgery under moderate hypothermic cardiopulmonary bypass
(CPB).
During the study period (6 months), at least, forty patients are randomly allocated into
following one of two groups using sealed envelopes: remifentanil-based propofol-supplemented
anesthesia regimen is employed in Group R and conventional balanced sevoflurane-sufentanil
anesthesia regimen in Group C, respectively.
Preoperative and intraoperative exclusion criteria Preoperative exclusion criteria 1) urgent
or emergent surgery, 2) left ventricle (LV) ejection fraction < 50%, 3) application of
intraaortic balloon pump (IABP), 4) myocardial infarction, 5) neurologic deficit, 6) hepatic
or renal impairment, 7) pacing, 8) inotropic medication, 9) neurologic deficit.
Intraoperative exclusion criteria
1) CPB application > 250 min, 2) transfused of packed red blood cell (pRBC) > 5 units, 3)
post-CPB use of double inotropic support > 30 min , 4) post-CPB pacing, 5) IABP 6) IABP 7)
postoperative hemodialysis, 8) excessive bleeding > 750 ml during postoperative 6 hour, 9)
reoperation due to excessive bleeding.
All data were collected by trained observers who did not participate in patient care and who
were blinded to the current study.
Anesthesia regimen After establishing routine invasive arterial blood pressure and
noninvasive patient monitoring such as pulse oximetry (SpO2), electrocardiography, bispectral
index (BIS) and cerebral oximetry, anesthesia is induced by two staff anesthesiologist (AA
and BB) using a target controlled infusion (TCI) of propofol (effect site concentration, Ce,
of 2.0 µg/ml) and remifentanil (plasma concentration, Cp, of 20 ng/ml with the time to reach
target concentration of 7 min) in Group R (by AA), and anesthesia is induced by bolus
injection of thiopental sodium 3-4 mg/kg and maintained using TCI- sufentanil (Cp of 0.4
ng/ml) in Group C (by BB). Muscle relaxation and tracheal intubation is facilitated by bolus
rocuronium under the guidance of peripheral neuromuscular transmission.
For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol
(variable Ce < 2.0 µg/ml) for maintaining BIS 40-60 in Group R [14], and TCI-sufentnail (Cp
of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value
and BIS < 60 in Group C, respectively. Rocuronium is continuously infused (3 µg/kg/min) in
both groups.
Controlled ventilation of O2/air mixture (FiO2 0.5-0.6) is performed with following setting
of anesthesia ventilator (ADU™, Datex-Ohmeda, Finland): tidal volume of 7 ml/ideal body
weight (calculated by obsolete formulas), respiratory rate maintain normocarbia (end-tidal
CO2 tension 35-40 mmHg) and inspiratory:expiratory ratio of 1:2.
Pulmonary artery catheter (Swan-GanzCCOmboCCO/SvO2, Edwards Lifesciences, Irvine, USA) and a
probe of transesophageal echocardiography were placed after anesthesia induction.
If high BIS score (> 60) persisted against the increase of sevoflurane to 1.5 MAC in Group C
or Ce of propofol to 2.0 μg/ml in Group R, bolus midazolam 2 mg is administered.
Surgery and CPB regimen All surgery is performed by one surgeon and 4 surgical assistants.
After performing sternotomy and administration of heparin 300 units/kg, arterial and venous
cannulations for CPB are performed at activated clotting time (ACT) > 450 sec and CPB was
conducted using reservoir, membrane oxygenator, roller pump and heat exchanger. Priming
volume for CPB was composed of normal saline, 20% mannitol, NaHCO3, 20% albumin, heparin,
antibiotics and calcium gluconate. The flow of CPB is initiated at 60 ml/kg/min and adjusted
by the current hemodilution and temperature.
Antegrade or retrograde administration of cold cardioplegic solution (20 ml/kg) consisting of
drained patient's blood, NaCl 6.43 g/L, KCl 1.193 g/L, CaCl2 0.176 g/L and MgCl2 3.253 g/L
(pH 7.4 at 4 - 8 °C) is applied as appropriate for cardiac protection after application of
aortic cross clamp (ACC).
Transfer to intensive care unit (ICU) and postoperative pain control After surgery, the
patients are transferred to the ICU in intubated status and received controlled or assisted
ventilation till the time of extubation. In Group R, remifentanil 0.25-0.3 μg /kg/min is
continued till the time of extubation.
For postoperative pain control, the intravenous patient control analgesia consisting of
alfentanil, ketorolac, and ondansetron is started at the time of sterna closure in Group C or
at 20 min before extubation in Group R, respectively.
Protocols of ventilator weaning and extubation The mode of ventilator is converted from
volume controled ventilation (CMV) to synchronized intermittent mandatory ventilation (SIMV)
when the following criteria were achieved: stable hemodynamics, self respiration, and the
respiratory rate 10-25 breaths/min [15].
The patients are extubated when the following criteria are achieved: awake state, stable
hemodynamics, normal airway reflex, respiratory rate 10-25 breath/min, SpO2 > 95% at FiO2 <
0.6, pH ≥ 7.3 and PaCO2 < 55 mmHg.
Measurements Operation time, CPB time, ACC time, intraoperative fluid administration
quantity, transfusion requirements, intraoperative urine output (UO), preoperative and
postoperative hematocrit (Hct) and preoperative and postoperative PaO2/FiO2 ratio are
recorded.
The duration from the end of surgery to the time of achieving BIS score > 80 (persisting > 3
min) (T-BIS80) [16], the duration from end of surgery to the time of initiating SIMV (T-SIMV)
and the duration from the end of surgery to the time of extubation (T-extubation) are
measured.
Statistical analysis The primary outcome variables are T-BIS80, T-SIMV, and T-extubation.
Statistics are performed using the program Sigmastat ver.3.1(Systat Software Inc, San Jose,
USA). Continuous variables were analyzed by a t-test, while categorical variables are by a
chi-square test between two groups. The data collected are expressed as mean and standard
deviation, numbers of patients or absolute numbers. A P value < 0.05 is considered
significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|